BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital Corp. The report, which reiterated a buy recommendation and $70 target price for BVXV, contained analysis highlighting a deal valued at approximately $2.4 billion for Eli Lilly and Company’s (NYSE: LLY) acquisition of DICE Therapeutics Inc. (NASDAQ: DICE), a biopharmaceutical company that develops oral therapeutic candidates – such as DC-806 and DC-853, both oral interleukin-17 (“IL-17”) inhibitors – currently in clinical development to treat chronic immune system diseases. “‘This deal between Eli Lilly and DICE Therapeutics illustrates the potential valuation that BiondVax could receive if it has positive early-stage clinical results.’ So far, several factors tip the scale in BiondVax’s favor,” a recent article, which contains excepts from the Aegis report, reads. “First, the company is focusing on a condition for which the mechanism of action of existing antibody-based treatments is well understood and has, in fact, been validated through clinical trials that have resulted in FDA approval. Secondly, a preclinical in vivo proof-of-concept study evaluating the company’s anti-COVID-19 NanoAb therapy virtually eliminated the virus from the lungs, caused milder and shorter illness, and had prophylactic properties. While the study evaluated an anti-COVID-19 drug, it showed, at least early on, the capabilities of NanoAbs. Furthermore, should BiondVax eventually receive FDA approval for its anti-IL-17 NanoAbs, precedent exists showing that the company and its shareholders stand to gain significantly from the potential market demand.”
To view the full article, visit https://ibn.fm/C880b
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com
MissionIR is powered by IBN
